Group 1 - The core point of the collaboration between Kanglong Chemical and Eli Lilly is the commercialization of the oral small molecule GLP-1 receptor agonist Orforglipron, with Eli Lilly investing $200 million to support Kanglong's technical capabilities [1] - Eli Lilly plans to invest a total of $3 billion in China over the next decade to enhance its production capacity for innovative drugs, aiming to build a more resilient and efficient local supply chain [1] - The Orforglipron drug is designed to be more convenient for oral administration and does not require refrigeration, which could improve accessibility for patients in remote areas with limited medical resources [1] Group 2 - China has a significant diabetes patient population of 148 million, accounting for 25.1% of the global total, and over 50% of adults are classified as overweight or obese, highlighting the urgent clinical needs [2] - The collaboration between Kanglong Chemical and Eli Lilly is a response to the growing patient population and unmet clinical demands, leveraging China's improving drug regulatory policies and industrial ecosystem [2] - Both companies aim to leverage their strengths to accelerate the localization of innovative drugs and contribute to the "Healthy China" initiative [2]

Core Insights - 康龙化成's stock opened over 12% higher and is currently up 11.83%, trading at HKD 20.80 with a transaction volume of HKD 149 million [1] Group 1: Partnership Announcement - 康龙化成 and Eli Lilly announced a production cooperation agreement for the first registered oral small molecule GLP-1 receptor agonist, Orforglipron [1] - Eli Lilly is expected to invest USD 200 million in 康龙化成 and support its technical capability development [1] - The collaboration on Orforglipron marks a significant milestone for 康龙化成 in its CDMO (Contract Development and Manufacturing Organization) business [1]

消息面上，3月11日，据康龙化成官微消息，公司与礼来公司共同宣布，达成关于首个申报注册的口服 小分子GLP-1受体激动剂Orforglipron的生产合作协议。根据协议，礼来公司预期投资康龙化成2亿美元 并支持其技术能力建设，未来将根据后续发展情况进一步扩大合作规模。此次与礼来公司就 Orforglipron达成制剂商业化生产合作，是公司制剂CDMO的重要里程碑。 智通财经APP获悉，康龙化成(03759)高开逾5%，截至发稿，涨5.43%，报19.61港元，成交额642.62万港 元。 ...

Core Viewpoint - Eli Lilly plans to invest a total of $3 billion over the next decade to expand its supply chain capacity in China, focusing on local production and supply of oral solid formulations, particularly for the GLP-1 receptor agonist Orforglipron [2][4]. Group 1: Investment Details - The investment marks Eli Lilly's second major commitment in China within two years and is part of the largest global production expansion plan in the company's history [1]. - The investment strategy combines internal expansion at the Suzhou facility with external collaborations, enhancing both production capacity and supply chain procurement [3][6]. - The total expected investment in China will rise to nearly $6 billion, with over 20 new drugs and indications anticipated in the next three years and more than 30 over the next decade [7]. Group 2: Product Focus - Orforglipron is the world's first registered oral small molecule GLP-1 receptor agonist, with expectations for it to be among the first to market globally [5]. - The Suzhou facility, established in 1996, is Eli Lilly's only owned production base in China, responsible for producing insulin and tablets for both domestic and international markets [4]. Group 3: Strategic Partnerships - Eli Lilly has formed a strategic partnership with WuXi AppTec, planning to invest $200 million to support its technological capabilities [2][6]. - The collaboration aims to enhance local manufacturing and supply of key innovations, with projected peak annual production capacity reaching several billion tablets [6].

香港联交所最新资料显示，3月5日，小摩减持康龙化成（03759）73.7481万股，每股作价18.1145港元， 总金额约为1335.91万港元。减持后最新持股数目约为2141.55万股，最新持股比例为5.94%。 责任编辑：卢昱君 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，3月5日，小摩减持康龙化成（03759）73.7481万股，每股作价18.1145港元， 总金额约为1335.91万港元。减持后最新持股数目约为2141.55万股，最新持股比例为5.94%。 ...

格隆汇3月10日丨根据联交所最新权益披露资料显示，2026年3月5日，康龙化成(03759.HK)遭JPMorgan Chase & Co.以每股均价18.1145港元减持好仓73.75万 股，涉资约1335.91万港元。 减持后，JPMorgan Chase & Co.最新持好仓数目为2141.55万股，持好仓比例由6.15%下降至5.94%。 | 麦格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 鳥 大 | 股份數目 | | | 精參閱上述*註 | 有投票權股期(日/月/ 份權益 | | | | | | | | | 份自分比 中) | | | | | | | | | 96 1 | | CS20260310E00182 | JPMorgan Chase & Co. | 1201(L) | | 737.481(L) | HKD 18.1145 | 21.415.472(L) | ...

香港联交所最新资料显示，3月5日，小摩减持康龙化成（300759）(03759)73.7481万股，每股作价 18.1145港元，总金额约为1335.91万港元。减持后最新持股数目约为2141.55万股，最新持股比例为 5.94%。 ...

智通财经APP获悉，香港联交所最新资料显示，3月5日，小摩减持康龙化成(03759)73.7481万股，每股 作价18.1145港元，总金额约为1335.91万港元。减持后最新持股数目约为2141.55万股，最新持股比例为 5.94%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 359,977,887 | RMB | | 1 RMB | | 359,977,887 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 359,977,887 | RMB | | 1 RMB | | 359,977,887 | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 359,977,887 | RMB | | 1 RMB | | 359,977,887 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 359,977,887 | RMB | | 1 RMB | | 359,977,887 | | 2. 股份分類 | 普通股 | 股份類別 | A ...